DelveInsight’s, “Influenza Pipeline Insight 2023,” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Influenza pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Influenza Emerging Drugs, the Influenza pipeline analysis report provides a 360° view of the Influenza pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Influenza pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Influenza Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Influenza clinical trials studies, Influenza NDA approvals (if any), and product development activities comprising the technology, Influenza collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key Takeaways from the Influenza Pipeline Report
To explore more information on the latest breakthroughs in the Influenza Pipeline treatment landscape of the report, click here @ Influenza Pipeline Outlook
Influenza Overview
Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death. Influenza causes significant loss of workdays, human suffering, and mortality.
Recent Developmental Activities in the Influenza Treatment Landscape
For further information, refer to the detailed Influenza Unmet Needs, Influenza Market Drivers, and Influenza Market Barriers, click here for Influenza Ongoing Clinical Trial Analysis
Influenza Emerging Drugs Profile
mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein that is considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines. Currently, it is in Phase III stage of clinical trial evaluation to treat patients suffering from Seasonal Influenza.
SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company’s proprietary technology, the DiversitAb™ platform, is designed to specifically bind to Type A and Type B influenza viruses. Pre-clinical data suggests that SAB-176 offers potentially broad protection against diverse influenza strains. A highly-potent, polyclonal antibody therapy for severe seasonal influenza, could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune compromised.
INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray under clinical development for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of severe complications. Based on its mechanism of action and intended route of administration, INNA-051 has the potential to address several viral respiratory pathogens across multiple patient populations with a variety of co-morbid conditions. INNA-051 antiviral efficacy is currently evaluated in a Phase 2a influenza-challenge conducted in healthy volunteers.
Codagenix has utilized a design platform to construct a live-attenuated, universal flu vaccine, CodaVax™-H1N1. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is being evaluated in Phase I stage of clinical trial evaluation to treat Influenza virus infections.
ALVR106 is an allogeneic, off-the-shelf, multi-virus specific VST therapy candidate designed to target diseases caused by the respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). In vitro data demonstrates that ALVR106 reactive cells have antiviral activity against each of the targeted viruses with minimal or no activity against non-virus-infected cells. This preclinical data supports the potential for antiviral benefit and safety of ALVR106 when administered to patients.
Influenza Pipeline Therapeutics Assessment
There are approx. 120+ key companies which are developing the therapies for Influenza. The companies which have their Influenza drug candidates in the most advanced stage, i.e. phase III include, Moderna.
Request a sample and discover the recent advances in Influenza Ongoing Clinical Trial Analysis and Medications, click here @ Influenza Treatment Landscape
Scope of the Influenza Pipeline Report
Dive deep into rich insights for drugs for Influenza Market Drivers and Influenza Market Barriers, click here @ Influenza Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Influenza Mergers and acquisitions, Influenza Licensing Activities @ Influenza Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/